The effect of omega-3 supplementation in COVID-19

The effect of omega-3 supplementation on inflammatory and biochemical markers in critical ill patients with COVID-19 a randomized clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151226025699N3

Enrollment

Registered

2020-05-20

Start date

2020-06-04

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group daily receive one capsule of omega-3 produced by Omid persina damavand company, Iran (1000 mg Omega-3 for each capsule, containing of EPAs+DHAs), through adding supp

Eligibility

Sex/Gender

All

Age

35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Written consent for participation Age over 34 years A diagnosis of COVID-19 based on symptoms such as severe pneumonia, fever, fatigue, dry cough, respiratory distress, and lungs involvement in the computed tomographic (CT) scan according to the doctor's confirmation

Exclusion criteria

Exclusion criteria: Not tendency to continue participating in the study Diagnosed cardiovascular and lung diseases which can disturb the study process A diagnosis of malignant tumors Recent use of chemotherapy drugs Having incomplete medical records Non-compliance with the omega-3 supplementation Consumption of omega-3 fatty acids supplementation during the last 3-month before the study

Design outcomes

Primary

Measure	Time frame
White blood cells (WBCs). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Neutrophils. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lymphocytes. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lactate dehydrogenase (LDH). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Creatine phosphokinase (CPK). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Cell blood count (CBC). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;C reactive protein. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.	—

Measure

Time frame

White blood cells (WBCs). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Neutrophils. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lymphocytes. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Lactate dehydrogenase (LDH). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Creatine phosphokinase (CPK). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;Cell blood count (CBC). Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.;C reactive protein. Timepoint: Baseline, 14-day after intervention. Method of measurement: using standard kits and the researchers gather these information from the lab test section of the ICU sheets.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Moslem

Sabzevar University of Medical Sciences

alirezamoslem@gmail.com+98 51 4401 1004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 15, 2026